Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revvity, Inc. (NYSE: RVTY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Revvity, a Massachusetts-incorporated health science and diagnostics company and member of the S&P 500 index, uses these filings to report material events, financial results, and governance changes related to its operations and securities.
Recent Form 8-K filings illustrate how Revvity communicates with the market. The company files 8-Ks to furnish earnings press releases for its quarterly results, to announce preliminary expectations for financial performance, and to provide presentation materials for major investor conferences such as the J.P. Morgan Healthcare Conference. Other 8-Ks disclose board and executive appointments and confirm details about its registered securities, including common stock and notes listed on the New York Stock Exchange.
Through its filings and accompanying earnings materials, Revvity explains the use of non-GAAP financial measures such as adjusted earnings per share, adjusted operating income, and organic revenue growth. The company describes how management uses these measures to evaluate operating performance, benchmark results, and inform compensation decisions, while also outlining the limitations of non-GAAP metrics and providing reconciliations to GAAP figures.
On this page, Stock Titan surfaces Revvity’s SEC filings with real-time updates from EDGAR and AI-powered summaries that clarify the purpose and implications of each document. Users can quickly understand the key points of quarterly results, changes in guidance, capital allocation actions, and governance updates without reading every line of the original filings. Access to these filings, including Form 8-Ks and related exhibits, helps investors, analysts, and researchers track how Revvity reports its financial condition, segment performance, and significant corporate events over time.
Revvity, Inc. executive reports tax-related share disposition. Victor Miriame surrendered 1,031 shares of common stock at $96.03 per share to cover tax withholding triggered by the vesting of restricted stock granted on February 16, 2023.
After this tax-withholding disposition, Miriame directly holds 18,122 shares of Revvity common stock. The transaction reflects a required withholding under his restricted stock agreement rather than an open-market sale.
Revvity, Inc. officer Tajinder S. Vohra reported a tax-related share disposition. On this Form 4, Vohra surrendered 566 shares of common stock at $96.03 per share to satisfy tax withholding triggered by the vesting of restricted stock granted on February 16, 2023.
These shares were not sold in the open market but withheld as required under the Restricted Stock Agreement. After this tax-withholding disposition, Vohra directly holds 13,965 shares of Revvity common stock.
REVVITY, INC. officer Anita Gonzales reported tax-withholding dispositions of 237 shares of common stock on February 17, 2026 at $96.03 per share. The shares were surrendered to cover tax obligations triggered by vesting of restricted stock units granted in 2023, 2024, and 2025, and were not open-market sales. Following these transactions, she directly owned 4,078 common shares.
REVVITY, INC. officer Maxwell Krakowiak reported two tax-related stock transactions. On February 17, 2026, he disposed of 1,457 and 902 shares of common stock at $96.03 per share.
According to the footnotes, these shares were surrendered to satisfy tax withholding obligations upon the vesting of restricted stock and restricted stock units originally granted on February 16, 2023, as required under his equity award agreements, rather than being discretionary open-market sales.
REVVITY, INC. officer Joel S. Goldberg reported a disposition of common stock tied to tax withholding. On February 17, 2026, he surrendered 1,733 shares of common stock at $96.03 per share to satisfy withholding taxes upon vesting of restricted stock granted on February 16, 2023, leaving 41,514 shares held directly.
An additional 63,709 shares are held indirectly in the Goldberg Irrevocable 2021 Trust for the sole benefit of his children, for which his spouse serves as trustee. Goldberg disclaims beneficial ownership of these trust-held shares except for any pecuniary interest.
REVVITY, INC. director and officer Prahlad R. Singh reported a tax-related share disposition. On the vesting of restricted stock originally granted on February 16, 2023, he surrendered 6,901 shares of common stock at $96.03 per share to satisfy tax withholding required under his Restricted Stock Agreement. After this transaction, he directly owns 113,312 common shares. An additional 46,583 common shares are held indirectly in an irrevocable trust for the sole benefit of his children, for which his spouse is trustee; he disclaims beneficial ownership of those trust-held securities except for any pecuniary interest.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G/A reporting a significant passive ownership stake in Revvity Inc. (common stock). The firm reports beneficial ownership of 22,447,103 shares, representing 19.8% of the class, with sole voting and dispositive power over these shares.
The filing notes that clients and funds advised by T. Rowe Price ultimately receive dividends and sale proceeds, and any delegated discretionary authority can be revoked. The T. Rowe Price Capital Appreciation Fund holds 14,366,588 shares, or 12.7% of the class. T. Rowe Price states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, and expressly denies beneficial ownership beyond its advisory role.
Revvity, Inc. reported equity compensation and tax withholding transactions for senior vice president, global operations, Tajinder S. Vohra. On February 4, 2026, Vohra received 4,448 time-based restricted stock units that vest in three equal annual installments starting on the first anniversary of the grant, bringing his directly owned common stock to 14,531 shares.
On the same date, 359 shares of common stock were surrendered at $101.13 per share to cover tax withholding tied to restricted stock units granted on February 4, 2025. Vohra also received a nonqualified stock option for 12,722 shares at an exercise price of $103.395, vesting in three equal annual installments beginning one year after grant and expiring on February 4, 2033. The filing also corrects an earlier Form 4 by clarifying the three-year vesting schedule for a prior restricted stock unit grant.
Revvity, Inc. insider Prahlad R. Singh, President, Chief Executive Officer and Director, reported multiple equity transactions dated February 4–5, 2026. On February 4, 3,421 shares of common stock were surrendered at $101.13 per share to cover tax withholding on vested restricted stock, and 26,796 time-based restricted stock units were granted, scheduled to vest in three equal annual installments beginning on the first anniversary of grant.
Singh also received a nonqualified stock option for 76,647 shares at an exercise price of $103.395, vesting in three equal annual installments beginning on the first anniversary of grant. On February 5, a previously granted option for 25,525 shares at $92.09 was exercised, and the resulting 25,525 shares of common stock were acquired, followed by market sales totaling 1,307, 12,186, 7,885, 3,079 and 1,068 shares at weighted average prices between $99.02 and $102.52, executed under a Rule 10b5-1 trading plan adopted on February 6, 2025.
After these transactions, Singh reported 120,213 shares of Revvity common stock held directly. An additional 46,583 shares are held indirectly by the Singh Family Trust of 2021 for the sole benefit of his children, with beneficial ownership disclaimed except for any pecuniary interest.